Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Oasis Capital
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Agreement September 10, 2020
Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.
Lead Product(s): NP-500
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Atlas Sciences
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.